Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. DeLauro Calls Hearing On FDA Drug Safety Highlighting Trasylol, Heparin

This article was originally published in The Pink Sheet Daily

Executive Summary

CBS News program “60 Minutes” is among the triggers for a “broad” hearing set for Feb. 27.

You may also be interested in...



Jerini’s Icatibant Falters in U.S., Wins In Europe

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

Jerini’s Icatibant Falters in U.S., Wins In Europe

FDA rejects orphan drug for hereditary angioedema, paving way for rivals to gain an edge.

U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official

Baxter heparin scare benefits American Pharmaceutical Partners, the other supplier of heparin to the U.S. market.

Related Content

Topics

UsernamePublicRestriction

Register

PS067276

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel